Hani Gabra is Professor of Medical Oncology at Imperial College London and Honorary Consultant Medical Oncologist at Imperial College Healthcare NHS Trust, based at the Hammersmith Campus of Imperial College.
He holds these appointments part-time concurrently with his position as Chief Medical Officer at BerGenBio ASA in Oxford, having previously held the position of Chief Physician Scientist and Vice President / Head of the Clinical Discovery Unit in Early Clinical Development within the IMED Biotech Unit at AstraZeneca in Cambridge.
Until May 2017 he was Head of the Molecular Therapeutics Unit, Deputy Head of the Division of Cancer and Director of the Ovarian Cancer Action Research Centre at Imperial College, and at Imperial College Healthcare NHS Trust he was also Head of Medical Oncology and Chair of the Cancer Research Committee. Until May 2017 he was also Associate Director and Lead of the Cancer Division (Division 1) of the NIHR Clinical Research Network for North West London.
Hani studied Medicine at the University of Glasgow and graduated with a BSc (Hons) in Molecular Biology and MB ChB in 1987. After obtaining MRCP(UK) in 1990, he undertook an MSc in Clinical Oncology and a PhD in Molecular Oncology from the University of Edinburgh. He then completed his specialist training in Cancer Medicine in Edinburgh and was CRUK Clinical Scientist and Consultant Medical Oncologist at the CRUK Edinburgh Medical Oncology Unit from 1998-2003, following which he took up his Chair appointment at Imperial College.
He is a Fellow of the Royal College of Physicians of Edinburgh and London.
His laboratory is involved in trying to understand the role of tumour suppressor genes in ovarian cancer, particularly how OPCML regulates networks of receptor tyrosine kinases and how WWOX acts to regulate taxane sensitivity.
His clinical / translational interests relate to the understanding of platinum resistance in ovarian cancer, and he has developed several molecular targets whose inhibition can reverse platinum resistance from laboratory to clinic; such targets include AKT, MTOR, HDAC4, STAT1 and the Folate Receptors.
Until September 2017 he was founding President of the European Translational Ovarian Cancer Network (EUTROC), a multinational group that undertakes science in ovarian cancer clinical trials, principally in the context of complex phase II clinical trials.
He previously sat on CRUK CTAAC funding committee for the UK and the INCa Scientific Evaluation Committee, Institut National Du Cancer of France.
et al., 2020, [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer, European Journal of Nuclear Medicine and Molecular Imaging, Vol:47, ISSN:0340-6997, Pages:1239-1251
et al., 2020, Oncologist-led BRCA ‘mainstreaming’ in the ovarian cancer clinic: A study of 255 patients and its impact on their management, Scientific Reports, Vol:10, ISSN:2045-2322
et al., 2019, Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial, The Lancet, Vol:394, ISSN:0140-6736, Pages:2084-2095
et al., 2019, Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker, Radiology, Vol:293, ISSN:0033-8419, Pages:374-383
et al., 2020, Proteomic analysis of malignant and benign endometrium according to obesity and insulin-resistance status using Reverse Phase Protein Array, ELSEVIER SCIENCE INC, Pages:57-72, ISSN:1931-5244